Differential management of mild-to-severe psoriasis with biologic drugs: An Italian Delphi consensus expert panel

Journal of Dermatological Treatment

Volumn 26, Issue 2, 2015, Pages 128-133

  Girolomoni, Giampiero ^a   Altomare, Gianfranco ^b   Ayala, Fabio ^c   Berardesca, Enzo ^d   Calzavara Pinton, Piergiacomo ^e   Chimenti, Sergio ^f   Martini, Patrizia ^g   Peserico, Andrea ^h   Puglisi Guerra, Antonio ⁱ   Antonio Vena, Gino ^j  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^e SPEDALI CIVILI   (Italy)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

^g Lucca Hospital   (Italy)

^h UNIVERSITY OF PADOVA   (Italy)

ⁱ Messina Hospital   (Italy)

^j Dermatology and Venereology Private Practice   (Italy)

more..

Author keywords

Clinical recommendations; Survey; Treatment choice

Indexed keywords

ANTIPSORIASIS AGENT; BIOLOGICAL PRODUCT; ETANERCEPT; TUMOR NECROSIS FACTOR ANTIBODY; USTEKINUMAB;

ALLERGIC REACTION; BIOLOGICAL THERAPY; DELPHI STUDY; DISCOID LUPUS ERYTHEMATOSUS; DISEASE SEVERITY; HEALTH CARE SURVEY; HUMAN; IMMUNOGENICITY; MILD HEPATIC IMPAIRMENT; ONLINE SYSTEM; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSORIASIS; REVIEW; CONSENSUS; PATHOPHYSIOLOGY; PROCEDURES; QUESTIONNAIRE;

BIOLOGICAL PRODUCTS; BIOLOGICAL THERAPY; CONSENSUS; ETANERCEPT; HUMANS; PSORIASIS; SURVEYS AND QUESTIONNAIRES;

EID: 84930789944     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2014.907466     Document Type: Review

References (55)

1. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377-85.
2. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146:891-5.
3. Samarasekera EJ, Neilson JM, Warren RB, et al. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol. 2013;133:2340-6.
4. Jones JG, Hunter D. Consensus methods for medical and health services research. BMJ. 1995;311:376-80.
5. Garcia Aparicio AM, Rey JR, Sanz AH, Alvarez JS. Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab. Clin Rheumatol. 2007;26:811-13.
6. Don BR, Spin G, Nestorov I, et al. The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis. J Pharm Pharmacol. 2005;57:1407-13.
7. Atzeni F, Sarzi-Puttini P, Botsios C, et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev. 2012;12:225-9.
8. Romero-Mate A, Garcia-Donoso C, Cordoba-Guijarro S. Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated review. Am J Clin Dermatol. 2007;8:143-55.
9. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371: 1665-74.
10. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371: 1675-84.
11. Esposito M, Giunta A, Mazzotta A, et al. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study. Dermatology. 2012;225: 312-19.
12. Ruiz-Villaverde R, Sanchez-Cano D, Abalos-Medina GM. Retrospective study of etanercept use in elderly people with psoriasis. Rev Esp Geriatr Gerontol. 2010;45:56-7.
13. Militello G, Xia A, Stevens SR, Van Voorhees AS. Etanercept for the treatment of psoriasis in the elderly. J Am Acad Dermatol. 2006; 55:517-19.
14. Pai MP. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. Pharmacotherapy. 2012;32:856-68.
15. Lebwohl M, Yeilding N, Szapary P, et al. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol. 2010;63:571-9.
16. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106-15.
17. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56:31 e31-15.
18. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010;69:522-8.
19. Gomez-Reino JJ, Carmona L, Angel Descalzo M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 2007;57:756-61.
20. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009;60:1884-94.
21. McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382:780-9.
22. Brunasso AM, Puntoni M, Gulia A, Massone C. Safety of antitumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology (Oxford). 2011;50: 1700-11.
23. Gisondi P, Dalle Vedove C, Girolomoni G. Patients with psoriasis have a higher prevalence of parental cardiovascular disease. Dermatology. 2011;222:330-5.
24. Setoguchi S, Schneeweiss S, Avorn J, et al. Tumor necrosis factoralpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J. 2008;156:336-41.
25. Lunt M, Watson KD, Dixon WG, et al. No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2010;62: 3145-53.
26. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med. 2004;116:305-11.
27. Strober B, Teller C, Yamauchi P, et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol. 2008;159:322-30.
28. Jamnitski A, Visman IM, Peters MJ, et al. Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study. Ann Rheum Dis. 2010;69: 1929-33.
29. Wu JJ, Poon KY, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148:1244-50.
30. Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol. 2002;86:123-30.
31. Mousa SA, Goncharuk O, Miller D. Recent advances of TNF-alpha antagonists in rheumatoid arthritis and chronic heart failure. Expert Opin Biol Ther. 2007;7:617-25.
32. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109:1594-602.
33. Muller-Ehmsen J, Schwinger RH. TNF and congestive heart failure: therapeutic possibilities. Expert Opin Ther Targets. 2004;8:203-9.
34. Food and Drug Agency. Update on the TNF-a blocking agents; 2001. Available from http://www.fda.gov/ohrms/dockets/ac/03/briefing/3930b1-01-b-tnf.briefing.htm. Accessed July 26, 2013.
35. Cabou C, Bagheri H, Cantagrel A, et al. Retrospective analysis of adverse effects of infliximab in a hospital rheumatology service. Therapie. 2003;58:457-62.
36. Lozeron P, Denier C, Lacroix C, Adams D. Long-term course of demyelinating neuropathies occurring during tumor necrosis factoralpha-blocker therapy. Arch Neurol. 2009;66:490-7.
37. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001;44:2862-9.
38. Lora V, Bonaguri C, Gisondi P, et al. Autoantibody induction and adipokine levels in patients with psoriasis treated with infliximab. Immunol Res. 2013;56:382-9.
39. Levine D, Switlyk SA, Gottlieb A. Cutaneous lupus erythematosus and anti-TNF-alpha therapy: a case report with review of the literature. J Drugs Dermatol. 2010;9:1283-7.
40. Maggi E, Vultaggio A, Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol. 2011;7: 55-63.
41. Cozzani E, Burlando M, Parodi A. Detection of antibodies to anti-TNF agents in psoriatic patients: a preliminary study. G Ital Dermatol Venereol. 2013;148:171-4.
42. Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis. 2013;72:1947-55.
43. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373:633-40.
44. Fenix-Caballero S, Alegre-Del Rey EJ, Castano-Lara R, et al. Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis. J Clin Pharm Ther. 2013;38:286-93.
45. Bogas M, Leandro MJ. Biologic therapy and pregnancy. A systematic literature review. Acta Reumatol Port. 2011;36:219-32.
46. Roux CH, Brocq O, Breuil V, et al. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford). 2007;46:695-8.
47. Vasiliauskas EA, Church JA, Silverman N, et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol. 2006;4: 1255-8.
48. Djokanovic N, Klieger-Grossmann C, Pupco A, Koren G. Safety of infliximab use during pregnancy. Reprod Toxicol. 2011;32:93-7.
49. Viktil KK, Engeland A, Furu K. Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150 000 pregnant women and expectant fathers. Scand J Rheumatol. 2012; 41:196-201.
50. Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:286-92; quiz e224.
51. Bhosle MJ, Feldman SR, Camacho FT, et al. Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis. J Dermatolog Treat. 2006;17:294-301.
52. Nast A, Sporbeck B, Rosumeck S, et al. Which antipsoriatic drug has the fastest onset of action?-systematic review on the rapidity of the onset of action. J Invest Dermatol. 2013;133:1963-70.
53. Strohal R, Puig L, Chouela E, et al. The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial). J Dermatolog Treat. 2013;24: 169-78.
54. Gordon KB, Gottlieb AB, Leonardi CL, et al. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J Dermatolog Treat. 2006;17:9-17.
55. Moore A, Gordon KB, Kang S, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol. 2007;56:598-603.